Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

NCT00400569 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Liposarcoma
Leiomyosarcoma
Fibrosarcoma
Malignant Fibrous Histiocytoma

Interventions

DRUG: Sunitinib Malate (SU011248)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]